PRKAG2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue lysate, Primary antibody: P10097(PRKAG2 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10097(PRKAG2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PRKAG2 antibody is a research tool designed to detect and study the PRKAG2 protein, a regulatory subunit of the adenosine monophosphate-activated protein kinase (AMPK) complex. AMPK is a critical energy sensor in eukaryotic cells, regulating metabolic homeostasis by responding to changes in ATP levels. The PRKAG2 subunit (γ2 isoform) plays a key role in modulating AMPK activity by binding adenosine nucleotides (AMP, ADP, ATP), which influences the enzyme’s ability to phosphorylate downstream targets involved in glucose uptake, lipid metabolism, and mitochondrial biogenesis.

Mutations in the PRKAG2 gene are linked to cardiac syndromes such as hypertrophic cardiomyopathy, Wolff-Parkinson-White (WPW) syndrome, and glycogen storage disease, making the PRKAG2 protein a focus in cardiovascular and metabolic research. Antibodies targeting PRKAG2 enable the detection of its expression, localization, and post-translational modifications in tissues and cell lines. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate its role in disease models, AMPK signaling pathways, and therapeutic interventions.

Commercial PRKAG2 antibodies are typically raised against specific epitopes, often validated for cross-reactivity in human, mouse, or rat samples. Researchers rely on these antibodies to dissect PRKAG2’s regulatory mechanisms and its contribution to pathologies, aiding in the development of targeted therapies for AMPK-related disorders.